Mark D. Eisner
- No difference observed in the risk of malignancy in patients exposed to omalizumab compared with controlsBy Roland Buhl, Carlos Fernandez Vidaurre, Martin Blogg, Jin Zhu, Mark D. Eisner, Janice Canvin and William BusseRoland Buhl1Pulmonary Department, University Hospital, Johannes Gutenberg-University, Mainz, GermanyCarlos Fernandez Vidaurre2Respiratory Medicine, Novartis Pharmaceutical Corporation, East Hanover, NJ, United StatesMartin Blogg3Respiratory Medicine, Novartis Horsham Research Centre, Horsham, West Sussex, United KingdomJin Zhu4Respiratory Medicine, Genentech Inc., South San Francisco, CA, United StatesMark D. Eisner4Respiratory Medicine, Genentech Inc., South San Francisco, CA, United StatesJanice Canvin3Respiratory Medicine, Novartis Horsham Research Centre, Horsham, West Sussex, United KingdomWilliam Busse5Department of Medicine, University of Wisconsin Medical School, Madison, WI, United States
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.